Semaglutide shows promise in reducing alcohol cravings and consumption. Could it be a future treatment for AUD?

(HealthDay News) — Low-dose semaglutide seems to reduce craving and certain drinking outcomes in alcohol use disorder (AUD), according to a study published online Feb. 12 in JAMA Psychiatry.

Novo Nordisk is providing direct-to-patient delivery of Wegovy (semaglutide) through the NovoCare Pharmacy program.

NovoCare Pharmacy will provide all dose strengths of Wegovy at a reduced cost of $499 per month for cash-paying patients ...

With shortages of its blockbuster obesity now declared resolved in the USA, Denmark’s Novo Nordisk (NOV: N) is moving to make ...